vinzolidine and Rectal-Neoplasms

vinzolidine has been researched along with Rectal-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for vinzolidine and Rectal-Neoplasms

Article	Year
Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum. Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:1 Vinzolidine, a semisynthetic vinca alkaloid, was studied as oral therapy in 30 patients with Kaposi's sarcoma, non-small cell lung cancer, colorectal cancer, and breast cancer. Substantial variations in morbidity were observed among the patients, some patients receiving doses up to 45 mg/m2 without toxicity while others had severe hematologic toxicity at doses as low as 25 mg/m2. Nausea/vomiting and diarrhea also occurred. Responses were seen in two of 11 patients with Kaposi's sarcoma but not in other patients. Unpredictable severe hematologic toxicity led to early closure of this study. The heterogeneity of patient tolerance may relate to variable oral drug bioavailability, and it is conceivable that vinzolidine could be administered more safely by the IV route. Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Sarcoma, Kaposi; Vinca Alkaloids	1985

Article

Year

Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum.

Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:1

Vinzolidine, a semisynthetic vinca alkaloid, was studied as oral therapy in 30 patients with Kaposi's sarcoma, non-small cell lung cancer, colorectal cancer, and breast cancer. Substantial variations in morbidity were observed among the patients, some patients receiving doses up to 45 mg/m2 without toxicity while others had severe hematologic toxicity at doses as low as 25 mg/m2. Nausea/vomiting and diarrhea also occurred. Responses were seen in two of 11 patients with Kaposi's sarcoma but not in other patients. Unpredictable severe hematologic toxicity led to early closure of this study. The heterogeneity of patient tolerance may relate to variable oral drug bioavailability, and it is conceivable that vinzolidine could be administered more safely by the IV route.

Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Sarcoma, Kaposi; Vinca Alkaloids

1985